Refine by
Applications
- Microbiome Therapeutics for Patients and Physicians
- Vaccine for COVID-19
- Freeze-Dried Hemostatic for Patients
- BSD-2000 - Deep Regional Hyperthermia System for Clinical
- Medical cannabis solutions for regulatory pathway sector
- Medical cannabis solutions for mental health costs sector
- IONICON PTR-TOF instruments deployed for COVID-19 detection in breath
- Drug Dolution for Liver Metastases
- Drug Dolution for Gastric Cancer
- Microbiota for Restoration Therapy
- Microbiota Based Product for Physician-Sponsored Studies
- Solution for Clinical Trials
- Solution for Access to Investigational Medicines
- Liquid Biopsy Technology for Hereditary Cancer Screening
Phase 1 Clinical Equipment & Supplies
226 equipment items found
Manufactured by:Adaptimmune LLC based inPhiladelphia, PENNSYLVANIA (USA)
Our ADP-A2AFP SPEAR T-cell product targets alpha-fetoprotein (AFP) is being investigated in an ongoing Phase 1 clinical trial for the treatment of patients with hepatocellular carcinoma (liver ...
Manufactured by:Shanghai Henlius Biotech, Inc based inShanghai, CHINA
HLX07, recombinant anti-epidermal growth factor receptor (EGFR) humanised monoclonal antibody injection independently researched and developed as biobetter. It was granted IND approvals to be evaluated in clinical trials in China and the United States. It demonstrated favorable safety and tolerability profile in a prospective, open-label, dose-escalation Phase ...
by:Zymeworks Inc based inVancouver, BRITISH COLUMBIA (CANADA)
ZW49 is a HER2-targeted antibody drug conjugate (ADC) developed using Zymeworks’ proprietary Azymetric™ and ZymeLink™ platforms. ZW49 is currently being evaluated in a Phase 1 clinical trial as a treatment for patients with locally advanced or metastatic HER2-expressing cancers that have progressed following treatment with ...
Manufactured by:BlueWillow Biologics based inAnn Arbor, MICHIGAN (USA)
BlueWillow’s intranasal vaccine technology has demonstrated safety and immunogenicity in Phase 1 clinical studies using a seasonal influenza vaccine. Several other ongoing BlueWillow programs — including intranasal vaccines for anthrax, pandemic influenza, RSV, HSV-2 and chlamydia — have recently advanced through successful ...
Manufactured by:TC BioPharm based inHolytown, UNITED KINGDOM
TCB002 is an unmodified allogeneic gamma delta T cell product, being initially used for the treatment of Acute Myeloid Leukaemia (AML). This product is currently undergoing a phase 1 clinical trial as part of a dose escalation and safety study, in partnership with ÚKHT, Institute of Hematology and Blood Transfusion, Prague. AML is a cancer ...
Manufactured by:Meissa Vaccines, Inc. based inRedwood City, CALIFORNIA (USA)
Meissa is developing MV-012-968, an intranasal (needle-free), adjuvant-free, live attenuated vaccine candidate, to protect infants and at-risk, older adults from RSV. In Phase 1 clinical trials, Meissa’s RSV vaccine candidate was well-tolerated, heavily attenuated, and stimulated a strong RSV-specific mucosal IgA response in participants ...
Manufactured by:Treos Bio Limited based inLondon, UNITED KINGDOM
In silico trials predicted that these peptides induce exceptionally broad T cell responses against at least 3 tumor-specific antigens in high proportion of patients, without need of biopsy. Phase 1 clinical study is completed to confirm the predictions in patients with metastatic colorectal cancer (NCT03391232, Hubbard et al ASCO 2020). ...
Manufactured by:Frontier Biotechnologies Inc. based inNanjing, CHINA
Licensed with exclusive rights for greater China from AFFiRiS AG, a clinical-stage biotechnology company in Austria, FB6001 is an investigational therapeutic peptide vaccine targeting PCSK9 to treat hypercholesterolemia. PCSK9 is a clinically validated target and FB6001 is a potential first-in-class immunotherapy for hypercholesteremia. FB6001 is expected to be ...
Manufactured by:Acorda Therapeutics, Inc. based inPearl River, NEW YORK (USA)
GGF2 is a member of the neuregulin growth factor family, and has been shown to promote recovery after neurological injury, as well as to enhance heart function in animal models of heart failure. GGF2 showed positive effects on cardiac function in the two Phase 1 clinical studies conducted to date. The Phase 1b trial ...
Manufactured by:Novavax based inGaithersburg, MARYLAND (USA)
In 5 separate studies, carried out in collaboration with the National Institute of Allergy and Infectious Diseases, active immunization with the Ebola GP vaccine was shown to be highly immunogenic and efficacious in preventing lethal disease in non-human primates challenged with EBOV. Our 2015 Phase 1 clinical trial demonstrated that our Ebola GP ...
Manufactured by:Sequoia Vaccines, Inc. based inSaint Louis, MISSOURI (USA)
Sequoia is developing a vaccine to reduce the recurrences of Urinary Tract Infections (UTI). Sequoia has completed its first clinical study in women with and without a history of recurrent UTI. In this study, Sequoia's investigational vaccine was highly immunogenic and well tolerated. In addition, it appears that the vaccine may indeed reduce the frequency of UTI. These ...
Manufactured by:T-Cure BioScience, Inc. based inSherman Oaks, CALIFORNIA (USA)
The Kita-Kyushu Lung Cancer antigen-1 (KK-LC-1) is a cancer/testis antigen (CTA) that is expressed in multiple solid tumors while restricted to germ line cells in normal tissues. T-Cure estimates that KK-LC-1 is expressed in 80% gastric cancer, 75% triple negative breast cancer (TNBC), 45% non-small cell lung cancer (NSCLC) and 40% cervical ...
Manufactured by:Ocean Biomedical based inProvidence, RHODE ISLAND (USA)
New therapeutic antibodies for effective treatment of NSCLC and other disorders. We are moving towards Phase 1 clinical trials of patented antibodies for the treatment of NSCLC. Our lead program, OCX-253 was chosen because it stimulates the B-Raf protooncogene while inhibiting apoptosis, NK cell accumulation and activation, LIM kinase 2, ...
Manufactured by:Meissa Vaccines, Inc. based inRedwood City, CALIFORNIA (USA)
Like Meissa’s RSV vaccine candidate, MV-014-212 offers significant potential advantages for global deployment, including needle-free intranasal administration, a single adjuvant-free dose to induce mucosal and systemic immunity, as well as a straightforward, economical, and scalable manufacturing process. A Phase 1 clinical study has been ...
Manufactured by:Kalaris based inWaltham, MASSACHUSETTS (USA)
Kalaris Therapeutics is focused on developing innovative treatments for retinal diseases, aiming to reduce the burden of frequent clinical visits for patients with retinal neovascular and exudative conditions. Their lead product, TH103, is a fully humanized, recombinant fusion protein designed for intravitreal delivery as an anti-VEGF agent. TH103 functions as a soluble decoy ...
Manufactured by:BridgeBio Pharma, Inc. based inPalo Alto, CALIFORNIA (USA)
SHP2 inhibition may relieve this negative effect, enhancing the patient's immune response to fight cancer proliferation. A Phase 1 clinical trial is planned ...
Manufactured by:Kiadis Pharma NV based inAmsterdam, NETHERLANDS
We believe this mechanism-of-action means Amlitelimab could be applicable to a range of autoimmune and inflammatory diseases. In our Phase 1 clinical trial in healthy volunteers, Amlitelimab was able to block T cell-driven skin inflammation while being well tolerated. We believe the immune-modulating mechanism of Amlitelimab has broad potential ...
Manufactured by:Gesynta Pharma AB based inStockholm, SWEDEN
Gesynta Pharma’s drug candidate GS-073 is expected to enter clinical phase I in 2022. It is currently in the final stages of preclinical development. This project will be addressing an indication with high unmet need, which is separate from systemic ...
Manufactured by:BCN Peptides S.A. based inSant Quintí de Mediona, SPAIN
Where can BCN Peptides assist your peptide project? BCN Peptides is an industrial manufacturer with the capacity to produce from milligram to multi-kg batches of pharmaceutical peptides. We are experts in the synthesis of long and complex New Chemical Entities. BCN Peptides ensures the highest qualities and shortest times thanks to our experience in the manufacturing of peptides for all clinical ...
by:STALICLA based inGeneve, SWITZERLAND
STALICLA is advancing a robust pipeline of both proprietary and partnered therapeutic ...